本文關(guān)鍵詞： 并購(gòu)績(jī)效 醫(yī)藥行業(yè) 因子分析法　出處：《北京化工大學(xué)》2015年碩士論文　論文類(lèi)型：學(xué)位論文

【摘要】：隨著2009年新醫(yī)改方案公布,國(guó)家希望加快醫(yī)藥行業(yè)管理的升級(jí)和產(chǎn)業(yè)集中度的提高。在如此的大環(huán)境之下,我國(guó)醫(yī)藥公司呈現(xiàn)出兼并收購(gòu)的趨勢(shì)。因此,研究醫(yī)藥企業(yè)的綜合并購(gòu)績(jī)效、科學(xué)分析評(píng)價(jià)其并購(gòu)績(jī)效尤為重要,它是衡量醫(yī)藥企業(yè)并購(gòu)成功與否的關(guān)鍵所在,評(píng)價(jià)制度和體系可以幫助企業(yè)提高對(duì)并購(gòu)績(jī)效的了解。只有完善企業(yè)的并購(gòu)制度,提高企業(yè)的并購(gòu)績(jī)效,才能真正增強(qiáng)其核心競(jìng)爭(zhēng)力,在實(shí)現(xiàn)戰(zhàn)略目標(biāo)的同時(shí)為企業(yè)創(chuàng)造更多的財(cái)富價(jià)值。該選題具有一定的理論研究意義與現(xiàn)實(shí)實(shí)踐意義。全篇共分為六部分。首先,主要介紹本論文選題背景意義、研究?jī)?nèi)容和方法、創(chuàng)新點(diǎn)和局限性。其次對(duì)并購(gòu)的概念進(jìn)行界定,同時(shí)介紹并購(gòu)績(jī)效的理論研究基礎(chǔ)和關(guān)于并購(gòu)績(jī)效的國(guó)內(nèi)外研究現(xiàn)狀。第三,分析我國(guó)醫(yī)藥行業(yè)現(xiàn)階段并購(gòu)發(fā)展?fàn)顩r,包括并購(gòu)制度背景、現(xiàn)狀分析以及存在的主要問(wèn)題。第四,總結(jié)醫(yī)藥企業(yè)的特點(diǎn),并以此提出一系列綜合評(píng)價(jià)指標(biāo),從而建立醫(yī)藥企業(yè)并購(gòu)績(jī)效評(píng)價(jià)的指標(biāo)體系。第五,采用案例研究法對(duì)HR醫(yī)藥商業(yè)集團(tuán)的并購(gòu)績(jī)效進(jìn)行研究,基于因子分析法對(duì)所選取的各個(gè)指標(biāo)分析評(píng)價(jià),提取三個(gè)公共因子并構(gòu)建綜合績(jī)效評(píng)分函數(shù)。通過(guò)對(duì)并購(gòu)前和并購(gòu)后的績(jī)效進(jìn)行對(duì)比,得出相關(guān)結(jié)論。評(píng)價(jià)結(jié)果表明：HR醫(yī)藥商業(yè)集團(tuán)的綜合并購(gòu)績(jī)效在并購(gòu)后一年出現(xiàn)明顯的快速下滑,之后逐年呈現(xiàn)緩慢上升的趨勢(shì)。評(píng)價(jià)結(jié)果同時(shí)也證明了多維度選取評(píng)價(jià)指標(biāo)的綜合優(yōu)越性以及選取因子分析法評(píng)價(jià)分析績(jī)效的客觀合理性。最后,針對(duì)HR醫(yī)藥商業(yè)集團(tuán)和我國(guó)醫(yī)藥行業(yè)并購(gòu)提出相關(guān)策略,同時(shí)說(shuō)明本文的局限性。研究發(fā)現(xiàn),HR醫(yī)藥商業(yè)集團(tuán)的并購(gòu)績(jī)效表現(xiàn)緩慢,在并購(gòu)的當(dāng)年績(jī)效迅速下降,但是總體來(lái)看還是呈上升趨勢(shì)。
[Abstract]:With the announcement of the new medical reform plan in 2009, the state hopes to speed up the upgrading of the management of the pharmaceutical industry and the improvement of the industrial concentration. Under such an environment, the pharmaceutical companies in our country are showing a trend of merger and acquisition. It is very important to study the comprehensive M & A performance of pharmaceutical enterprises and to evaluate their M & A performance scientifically, which is the key to measure the success of M & A of pharmaceutical enterprises. The evaluation system and system can help enterprises improve their understanding of M & A performance. Only by perfecting the M & A system of enterprises and improving their M & A performance can they truly enhance their core competitiveness. This topic has some theoretical and practical significance. The whole article is divided into six parts. First of all, it mainly introduces the background significance of this thesis. The research contents and methods, innovation points and limitations. Secondly, the concept of M & A is defined, at the same time, the theoretical basis of M & A performance and the domestic and foreign research status of M & A performance are introduced. Third, This paper analyzes the current development of M & A in the pharmaceutical industry of China, including the background of M & A system, the present situation and the main problems. 4th, summarizes the characteristics of pharmaceutical enterprises, and puts forward a series of comprehensive evaluation indexes. Thus, the index system of M & A performance evaluation of pharmaceutical enterprises is established. 5th, the case study method is used to study the M & A performance of HR pharmaceutical commercial group, and the selected indicators are analyzed and evaluated based on factor analysis. Three common factors were extracted and a comprehensive performance scoring function was constructed. The evaluation results show that the performance of comprehensive M & A of the W HR Pharmaceutical Commercial Group declined rapidly in the year after M & A. At the same time, the evaluation results also prove the comprehensive superiority of multi-dimension evaluation index and the objective rationality of selecting factor analysis method to evaluate the performance. This paper puts forward the relevant strategies for the M & A of HR and China's pharmaceutical industry, and explains the limitations of this paper. The research finds that the performance of M & A of HR Pharmaceutical Commercial Group is slow, and the performance of M & A in the year of M & A is declining rapidly. But overall, there is an upward trend.
【學(xué)位授予單位】：北京化工大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類(lèi)號(hào)】：F271;F426.72

【參考文獻(xiàn)】

相關(guān)期刊論文 前5條

1 楊曉嘉,陳收;上市公司并購(gòu)績(jī)效矩陣評(píng)價(jià)模型研究[J];財(cái)經(jīng)理論與實(shí)踐;2005年02期

2 姜薇薇;韓旭明;孫海波;王麗敏;;上市公司績(jī)效評(píng)價(jià)問(wèn)題研究——基于吸引子傳播聚類(lèi)方法的分析[J];當(dāng)代經(jīng)濟(jì)研究;2014年04期

3 顧海峰;謝曉晨;;中國(guó)企業(yè)跨國(guó)并購(gòu)績(jī)效評(píng)價(jià)的理論與實(shí)證研究——來(lái)自2000-2010年中國(guó)企業(yè)的經(jīng)驗(yàn)證據(jù)[J];經(jīng)濟(jì)與管理評(píng)論;2013年06期

4 張方方;;中國(guó)上市公司并購(gòu)的價(jià)值效應(yīng)的EVA分析[J];武漢大學(xué)學(xué)報(bào)(哲學(xué)社會(huì)科學(xué)版);2007年06期

5 王斐波;周燕;;醫(yī)藥上市公司并購(gòu)績(jī)效實(shí)證分析[J];現(xiàn)代營(yíng)銷(xiāo)(學(xué)苑版);2013年09期

，

本文編號(hào)：1541339